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Introduction
Neuromyelitis optica (NMO) is an autoimmune 
inflammatory disorder of the central nervous system 
that predominantly targets the optic nerve and spinal 
cord. Until recently, NMO was thought to be a clinical 
variant of multiple sclerosis (MS). However, clinical 
features, neuroimaging, immunological, and histo-
pathological characteristics have now been identified 
which distinguish NMO from MS. Clifford and Gault 
summarized the salient features of the disease in 
1894, though descriptions of the disease appeared 
much earlier. The typically long spinal cord segmen-
tal involvement, longitudinally extensive transverse 
myelitis (LETM) and neutrophilic pleocytosis in the 
cerebrospinal fluid (CSF) became incorporated into 
the first Wingerchuk diagnostic criteria for NMO in 
1999.1 Subsequently, the discovery of anti AQP4-
IgG2 led to the revised Wingerchuk criteria in 2006.3 
The term “NMO spectrum disorders”4 (NMOSD) 
encompasses forms of NMO that do not satisfy the 
2006 criteria. Examples include isolated unilateral or 
simultaneous bilateral or recurrent optic neuritis 
(ON); isolated or recurrent transverse myelitis (TM); 
typical NMO brain lesions (hypothalamus, corpus 
callosum, brainstem, periventricular) with or without 
detectable anti AQP4-IgG autoantibody. Thus, the 
diagnostic criteria have been refined and the spectrum 
of clinical manifestations in NMO has expanded in 
recent years.
NMO occurs worldwide in diverse races and cultures; 
however, the global incidence and prevalence of this 
disease is incompletely characterized. More specifi-
cally, it is unclear whether disease frequency, clinical 
course, severity, and gender predominance vary 
between geographical regions. Obtaining epidemio-
logical and demographic data for a relatively uncom-
mon disorder like NMO is challenging. Very few 
published reports of NMO have appeared from emerg-
ing nations. Access to magnetic resonance imaging 
(MRI) centers varies, as do laboratory facilities for 
CSF analysis and anti AQP4-IgG detection. Hence, 
timing of the MRI after an attack of myelitis and blood 
sampling for anti AQP4-IgG testing may vary. 
Furthermore, lack of uniformity of survey methods, 
disease definitions, and diagnostic criteria complicate 
interpretation of the literature.
A small proportion of patients with NMO are seron-
egative for anti AQP4-IgG, and may represent a het-
erogeneous spectrum of NMO or disease mimics 
(including MS and other diseases such as sarcoidosis 
and paraneoplastic disorders). Thus, studies that 
include all clinically defined NMO patients are 
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difficult to compare with those selecting only anti 
AQP4-IgG-positive patients. In addition, assays for 
detection of anti AQP4-IgG vary with regard to their 
sensitivity and specificity. Although most contempo-
rary assays perform well in a high-probability patient, 
when used for population screening the seropositive 
rate can vary by two-fold or greater between assays of 
different specificity.5,6 The initial AQP4-IgG immu-
nofluorescence assay that was developed is the least 
sensitive.2,6 The cell-based assay (CBA), although 
labor intensive and less suited to mass screening, is 
most sensitive and specific for use in clinical diagno-
sis.6,7 Thus, differences in diagnostic criteria and anti 
AQP4-IgG assays may account for heterogeneity in 
epidemiologic data, and may explain some of the 
observed discrepancies in interpretation.
The goal of this review article is to assess major epi-
demiological and hospital-based studies to estimate 
incidence and prevalence of NMO in different geo-
graphic regions, and to provide insights into the dif-
ferences and similarities of demographic and clinical 
features of NMO among diverse populations.
Methods
In this paper, we reviewed the published reports of 
population-based studies, hospital-based retrospec-
tive chart reviews, and data from NMO registries. We 
queried the PubMed database from the years 1999–
2014. The search terms used included “neuromyelitis 
optica”, “Devic’s disease”, “incidence”, “prevalence”, 
“epidemiology”, “demography” and “clinical fea-
tures”. In total, 48 studies were examined. Of these, 
seven population-based epidemiological studies 
(Table 1) and nine hospital-based studies were 
included for comparative analysis of clinical and 
demographic features (Table 2). All studies that were 
included had utilized Wingerchuck 1999 or 2006 cri-
teria, and results of anti AQP4 - IgG testing were 
available. Lastly, to integrate a global demographic 
perspective, selected data obtained from the Atlas of 
MS 2013 (www.atlasofms.org) were also included in 
the analysis.
Population-based studies
While data from population-based studies are likely 
to be more robust, several factors make direct com-
parisons across such studies challenging. For exam-
ple, variability in the source data (e.g. clinic, health 
insurance data, or population based), diagnostic crite-
ria, inclusion of seronegative individuals, definition 
of NMOSD, and the particular anti AQP4-IgG assay 
used are important factors undoubtedly influencing 
the results. The ethnic mix of the populations studied 
may also influence the prevalence rates. In addition, 
most published studies have focused on adults.
Incidence
There have been several recent studies from Denmark, 
West Indies, Cuba, the UK, and Austria from which 
unadjusted incidence rates (per 100,000) could be cal-
culated (Table 1).8–12 In a Danish population compris-
ing 99% whites, an incidence rate of 0.40 (95%CI 
0.30–0.54) was found to be the highest among the five 
studies included.8 A French West Indies study9 found 
that the age and sex-standardized incidence was 0.22 
(95%CI 0.04–0.38), and remained consistent between 
1992 and 2007. While the latter study included only 
NMO cases in which Wingerchuk criteria were fully 
met, the Danish study included all individuals carry-
ing the diagnosis of NMO, regardless of whether they 
met these criteria. Thus, selection criteria may influ-
ence incidence rates of the disease. A Cuban study 
included white subjects of Spanish descent, African, 
and those of mixed racial origins.10 Here, an overall 
incidence rate of 0.05 was observed, and was similar 
across ethnic groups, but varied from 0.12–1.76 
across geographical regions of Cuba. The incidence 
rate in Merseyside, UK, a population consisting of 
88% whites, was found to be 0.08 (95%CI 0.03–
0.16).11 An Austrian study12 reported an incidence rate 
of 0.05 (95% CI 0.01–0.31), in an all-white 
population.
Prevalence
Several studies have measured prevalence (per 
100,000) in NMO. The prevalence was 4.4 in 
Denmark8 (95%CI 3.1–5.7), 1.96 among the white 
population of Wales,13 0.72 in Merseyside, UK,11 2.3 
in the French West Indies9 and 0.5210 in Cuba. The 
vast majority of patients in an NMOSD cohort in 
Austria12 (71/73, all whites) were seropositive. The 
prevalence rate of NMO was 0.77 per 100,000.12 
Prevalence data are also available from Japan and 
India. In Japan, a prevalence rate of 0.9 per 100,000 
(95%CI 0.2–2.5) was determined,14 while in southern 
India it was 2.7/100,000.15 Collectively, these studies 
suggest a relatively wide range in prevalence, includ-
ing differences in geographic and ethnic cohorts. The 
Danish study was the only one that included limited 
forms of NMO.
Hospital-based studies
Nine hospital-based observational studies were identi-
fied (Table 2), four from Europe,12,16–18 one each from 
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the USA,19 Brazil,20 Austria,12 India,21 and Korea.22 All 
of these studies used Wingerchuk 2006 diagnostic cri-
teria except the Spanish18 study (which used 1999 and 
2006 criteria). Median time to second attack was 8–12 
months (range 1–216 months). Mortality ranged from 
2.9–25% and was disease related in the majority of 
cases. Analysis of registry-based data suggests that the 
proportion of patients with NMO among all demyeli-
nating disorders varies significantly among different 
geographic regions: 1.2% in Italy,23 1–2% in the USA,19 
13.7% in India,21 and 39.3% in Thailand.24 The study 
from Thailand underscores the need for supportive 
radiological criteria that justify the clinical diagnosis. 
Several anti AQP4-IgG seropositive patients with a 
diagnosis of MS, in retrospect had radiological and 
clinical features of NMO.
Effect of age
There are geographic differences with respect to 
NMO and patient age. From prevalence studies, 
median age at onset was found to be 30.5 years in 
Cuba,10 39.5 years in South East Wales,13 30 years in 
Denmark,8 and 55.2 years in Austria.12 These differ-
ences may reflect variations in case ascertainment and 
diagnostic criteria, access to medical care, and/or eth-
nicity. In the Cuban study, blacks were older than 
non-blacks at disease onset; however, there were no 
differences between other subgroups.10 The mean age 
of onset of NMO ranged from 32.6–45.7 years in 
major case series (Table 2). In a study comparing 
seropositive individuals (based on the CBA) in the 
UK, and Japan, Afro-Caribbeans experienced earlier 
disease onset than white and Asian patients.24 
Pediatric onset is rare, with <5% of cases presenting 
prior to age 18 in two studies.25,26 In contrast, late-
onset NMO/NMOSD, defined as onset age >50 years, 
accounted for 108/430 (25%) in a large multicenter 
cohort study.27 Compared with patients with adult-
onset NMO, those with pediatric NMO more fre-
quently have brain involvement, experience milder 
locomotor disability, and develop significantly earlier 
visual disability.25 In a German study that contrasted 
clinical presentation of seropositive and negative 
NMO patients, the proportion of anti-AQP4-IgG- 
positive patients appeared to increase with age; 
however, mean age at onset did not differ among 
seronegative and seropositive patients.17 The largest 
study assessing serological status and age is that from 
the Mayo clinic, which compared the demographics 
of over 50,000 patients referred for NMO-IgG test-
ing.26 Similar to the German study,17 the proportion of 
seropositive females was shown to increase with age, 
and was highest in the >65 year-old group, accounting 
for 12% of the entire seropositive cohort.
Gender ratio
As with many autoimmune diseases, NMO and 
NMOSD are more common in females, ranging from 
66–88% of the patient population.8,9,16 One study 
reported an 89% female predominance when includ-
ing only cases with relapsing NMO. Even prior to the 
discovery of anti AQP4-IgG, relapsing NMO was 
known to be more prevalent in females (83%), 
whereas a more equal female/male distribution was 
detected in monophasic disease (48%). Anti AQP4-
IgG positivity was associated with relapsing disease 
with rates of 81–91%,17,28 particularly when CBA is 
used. Among patients with LETM, females represent 
86% of anti AQP4-IgG seropositive compared with 
44% of seronegative individuals.29 The variation 
across studies may be influenced by limited patient 
numbers in those conducted within specialized cent-
ers. Moreover, there may be racial and geographical 
effects. For example, in a comparative study from dif-
ferent populations24 females represented 82% of 
patients in whites from the UK, compared with 75% 
in Afro-Caribbeans and 98% in a Japanese cohort. In 
an all-white Austrian cohort, the female ratio was 
87% for all AQP4-IgG-positive patients12 while it 
reached 100% in a French West Indian cohort.
Disease onset, course and severity
Several multicenter registry-based observational, ret-
rospective studies (Table 2) provide information 
about clinical course and disease severity. Some com-
mon findings emerged from these studies. The pre-
senting symptom was usually either ON or TM, 
especially among seropositive patients. Simultaneous 
TM and ON, bilateral ON, and monophasic course 
were relatively more common presentations among 
seronegative patients.16,17, 29 Males and females were 
similarly affected in this subgroup.17,29 Age at disease 
onset appears to have a bearing on disability type. In 
a comparative study, Kitley et al.25 found that patients 
in the UK had young-onset disease commonly pre-
senting with ON and had a high risk of visual disabil-
ity. An older age of onset was significantly associated 
with motor disability, in both Japanese and UK 
cohorts. Jarius et al.17 have further identified distinct 
clinical features for NMO patients based on anti 
AQP4-IgG serological status. Seropositive women 
had more severe clinical attacks than males in this 
cohort, as evidenced by high lesion load in the spinal 
cord and other types of co-existing autoimmunity. 
Overall, seropositive and seronegative patients did 
not differ in terms of age of onset, time to relapse, 
relapse rates, rate of Expanded Disability Status Scale 
(EDSS) progression, and mortality rate. Irrespective 
of anti AQP4-IgG serological status, predictors of 
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outcome included development of tetraparesis during 
the first attack of TM, and multiple attacks of TM in 
the first year. Distribution of brain lesions was differ-
ent depending on anti AQP4-IgG status. Periaqueductal 
grey matter, hypothalamic, and area postrema lesions 
may be more often seen in seropositive patients.30 In 
the Danish study, NMO-IgG seropositive patients fre-
quently developed brainstem lesions and LETM dur-
ing the decade of follow-up.31 A study from Barcelona, 
which focused on LETM, found that EDSS at presen-
tation was predictive of the recurrence risk and 
disability.32
Ethnicity and disease course
Ethnicity appears to be an influential factor in NMO 
and NMOSD. In the Cuban study10 patients of African 
origin were older, had more relapses, abnormalities in 
brainstem-evoked potentials, and acquired more 
lesions on brain MRI than comparator patients. 
African Americans in the US18 had significantly more 
brainstem MRI abnormalities than white Americans. 
Kitley and colleagues25 compared the disease course 
and prognostic factors for seropositive NMO patients 
in the UK (n=59) and Japan (n=47). In the UK group, 
45/59 were white, 12/59 were Afro-Caribbean, and 
two were Asian. Age of onset and ethnicity were asso-
ciated with outcome. Young white patients presented 
with ON, and had greater visual disability. In contrast, 
older patients of both ethnicities presented with mye-
litis and greater motor disability. The Afro-Caribbean 
subgroup was significantly younger at onset than both 
white and Japanese patients (mean 28.0 ± 13.1 years 
and 44.9 ± 17.2 years, respectively). Initial events 
more commonly included those of brain/brainstem in 
Afro-Caribbean patients compared with white and 
Japanese, and uniformly had relapsing NMO com-
pared with 80% in the other ethnicities. Annualized 
relapse rate among Afro-Caribbean patients was com-
parable with that of white patients but higher than that 
of the Japanese. Visual disability was more severe in 
non-white patients. In contrast, white patients had a 
later age of onset and worse motor outcomes. In the 
study conducted in Cuba and French West Indies,9,10 
lack of recovery after the first attack and a higher rate 
of attacks during the first year of disease were strong 
independent prognostic factors of mortality.
Population genetics
Initial epidemiological studies have suggested ethnic-
ity-based differences in genetics of NMO patients. 
However, no specific genetic determinants of NMO 
disease have thus far been identified. The genetic basis 
for these ethnic differences is not well understood, but 
the human leukocyte antigen (HLA) system remains 
an obvious candidate. Studies from Japan have ana-
lyzed the clinical and genetic features of the optico-
spinal form of multiple sclerosis (OSMS), a disease 
entity which may overlap with NMO. In that popula-
tion, conventional MS was associated with HLA-
DRB1*1501 whereas OSMS/NMO was associated 
with HLA DPB1*0501.33 Other population studies of 
HLA in NMO indicate that the DRB1*030134–36 and 
DRB1*1037 alleles are associated with increased risk.
Familial NMO has been described. In the largest 
study, Matiello et al.38 identified 12 families (five 
Asian, four Latino, two African, one white) with a 
total number of 25 affected individuals, 19 of whom 
were AQP4-IgG positive. The role of environmental 
influences in the etiopathogenesis of NMO has not 
been established. Migration studies are needed to 
explore whether risk is mutable with migration and 
how this relates to age at migration.
Insights into NMO epidemiology from the 
Atlas of MS Database
In 2013, a questionnaire designed to update the MS 
global dataset added a number of queries relating to 
NMO, including prevalence, incidence, gender ratio, 
mean age of onset, diagnostic criteria used, and thera-
peutic options. This questionnaire received notifica-
tions of 10,567 cases obtained from 40 of 107 
countries participating in the survey. Roughly one-
third of the patients reported were from Japan (3500), 
creating potential bias. Data on prevalence (expressed 
as cases per 100,000) were available from 35 coun-
tries. In temperate zones, Central European countries 
had a prevalence ranging from 0.23 in Belgium to 2.0 
in Norway, while Denmark (4.4) and The Netherlands 
(5) had comparatively high prevalence. By compari-
son, NMO prevalence among the Japanese population 
was 2.8. South Africa and Paraguay had the highest 
prevalence (5), followed by French West Indies (4.2). 
In the Middle East, the projected figures ranged from 
0.16–2 and in South East Asia from 0.43–2.7. These 
widely disparate reports, particularly among European 
countries, may have resulted from differing method-
ologies involved in the collection of source data. No 
data were available from most regions of the African 
continent, Eastern Europe, parts of Central America, 
and South Asia. In each population studied patients 
were predominantly female, with ratios ranging from 
1.0 in Ireland to 10.1 in Paraguay. Overall the mean 
age of onset ranged from 25.0–45.7 years. The MS 
database provided information from a variety of 
countries across the globe. In most instances, the find-
ings were not supported by published literature and 
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were often sourced from single or few individuals 
with an interest in the subject. Resource-poor coun-
tries had few neurologists and limited MRI centers, 
and diagnostic NMO-IgG testing was limited or non-
existent. These factors hampered the reliability of the 
survey.
Conclusions
NMO epidemiology has largely been based on rela-
tively small populations and data from tertiary hospi-
tals. Many of these initial studies have yielded 
inconsistent findings. Confounding factors include the 
use of non-standardized diagnostic criteria, variability 
in assays for anti-AQP4 antibody, inconsistent inclu-
sion of NMO-IgG seronegative patients, small study 
cohorts, and potential for selection bias. These factors 
limit the comparative assessment and statistical power 
of epidemiologic studies in NMO and NMOSD. While 
differences in ethnicity appear to impact clinical dis-
ease course and NMO-IgG status, recent studies have 
disclosed similarities in incidence and prevalence of 
NMO. Female predominance is commonly seen and 
appears congruent with NMO-IgG seropositive status, 
which itself associates with a relapsing phenotype. 
HLA haplotype associations have been hypothesized, 
but the genetic basis for differences in risk, severity, 
therapeutic efficacy, or clinical outcomes remains 
uncertain. Larger adequately powered epidemiologi-
cal studies applying standardized definitions and 
methodologies are needed before specific conclusions 
can be drawn. The advent of more specific diagnostic 
criteria, improved diagnostic assays and methods, and 
a better understanding of the basic immunology of 
NMO and NMOSD are likely to advance these goals. 
In turn, these steps should improve consistency in 
diagnosis and enhance study cohorts for the most 
informative clinical trials for NMO.
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